Undisclosed mRNA therapeutic / GC Biopharma, Immetas Therap - LARVOL DELTA

Immetas Therapeutics and GC Biopharma Announce Research Collaboration to Discover and Develop mRNA Therapeutics to Treat Autoimmune Diseases (Businesswire) - "Immetas Therapeutics and GC Biopharma today announced that they have entered into a research collaboration to discover and develop novel mRNA therapeutics for the treatment of a broad range of autoimmune diseases....Under the collaboration agreement, Immetas will be responsible for identifying therapeutic targets, generating and characterizing payload molecules, defining disease indications and creating translational and clinical development strategies. GC Biopharma will be responsible for the design and manufacture mRNA constructs for payload expression, selection of LNP and delivery formulations, and characterization of the combination product candidates. Both companies will jointly conduct subsequent development activities. Additional terms were not disclosed."

Licensing / partnership • Immunology